arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Bicycle Therapeutics plc

BCYC Health Care Biotechnology: Pharmaceutical Preparations
$4.30
Today
as of Sep 4, 16:46 ET
Last 30 days +9.14% Jul 28 → Sep 04
$3.82 $3.97 $4.12 $4.28 $4.43 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$4.20
High
$4.30
Low
$4.20
Volume
$157,467
Avg Vol
$372,178
Mkt Cap
$297M
P/E (TTM)
—
Beta
—
52w High
$9.16
52w Low
$3.75
Div Yield
—
Shares Out
$70M

Recent Press Releases & News last 60 days · 1 item

Jul 30 · 11:00 PR Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Overview

52-week range
$3.75
$9.16
10% of range
Avg surprise (last 2)
-11.2%
Avg reaction (last 1)
+6.1%
100% positive
Latest IV / EM
216%
EM ±33.7% · $4 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.41$-1.21$-1.01$-0.82$-0.62 Actual $-1.30Actual $-1.41Actual $-1.26Actual $-0.62Actual $-0.77Actual $-0.74Actual $-0.88Est $-0.86Actual $-1.14Est $-0.95Actual $-0.85Actual $-0.87Actual $-0.72 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$-79M$-56M$-33M$-10M$12M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.72 — — — — financials
Tue Mar 31, 2026Mar 2026 $-0.87 — — — — financials
Tue Sep 30, 2025Sep 2025 $-0.85 — — — — financials
Fri Aug 8, 2025Jun/2025 $-1.14 $-0.95 -20.0% — — earnings
Thu May 1, 2025Mar/2025 $-0.88 $-0.86 -2.3% — +6.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.74 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.77 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.62 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.26 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.41 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.30 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$629,000$887,000—$12M$3M$10M—$3M
Cost of revenue————————
Gross profit————————
Operating income$-55M$-65M—$-66M$-87M$-70M—$-64M
Net income$-50M$-61M—$-59M$-79M$-61M—$-51M
EPS (diluted)$-0.72$-0.87—$-0.85$-1.14$-0.88—$-0.74

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$510M$559M$628M$648M$721M$793M$880M$891M
Inventory————————
Total current assets$575M$619M$683M$739M$804M$856M$929M$966M
Total assets$607M$652M$718M$764M$832M$884M$957M$997M
Long-term debt————————
Total liabilities$96M$98M$108M$145M$163M$144M$164M$166M
Total equity$510M$554M$610M$618M$669M$740M$793M$831M

Implied volatility — last 90 days

16%107%198%290%381% Jun 07 — IV 198% · EM ±27.4%Jun 08 — IV 37% · EM ±4.9%Jun 09 — IV 38% · EM ±4.8%Jun 10 — IV 53% · EM ±6.2%Jun 11 — IV 55% · EM ±6.1%Jun 12 — IV 60% · EM ±6.2%Jun 15 — IV 83% · EM ±6.0%Jun 16 — IV 62% · EM ±3.7%Jun 17 — IV 90% · EM ±3.7%Jun 19 — IV 85% · EM ±18.8%Jun 22 — IV 48% · EM ±10.1%Jun 23 — IV 79% · EM ±16.2%Jun 24 — IV 76% · EM ±15.2%Jun 25 — IV 45% · EM ±8.7%Jun 26 — IV 32% · EM ±6.1%Jul 01 — IV 78% · EM ±13.1%Jul 02 — IV 135% · EM ±21.8%Jul 03 — IV 140% · EM ±21.8%Jul 20 — IV 25% · EM ±6.0%Jul 21 — IV 26% · EM ±6.0%Jul 22 — IV 26% · EM ±5.9%Jul 23 — IV 21% · EM ±4.8%Jul 24 — IV 58% · EM ±12.9%Jul 27 — IV 42% · EM ±8.9%Jul 28 — IV 43% · EM ±8.9%Jul 29 — IV 58% · EM ±11.7%Jul 31 — IV 54% · EM ±10.4%Aug 03 — IV 51% · EM ±9.0%Aug 04 — IV 52% · EM ±8.9%Aug 05 — IV 53% · EM ±8.9%Aug 06 — IV 39% · EM ±6.3%Aug 07 — IV 69% · EM ±10.8%Aug 10 — IV 35% · EM ±4.9%Aug 11 — IV 28% · EM ±3.6%Aug 12 — IV 39% · EM ±4.9%Aug 17 — IV 75% · EM ±6.2%Aug 18 — IV 381% · EM ±27.6%Aug 24 — IV 22% · EM ±4.6%Aug 25 — IV 17% · EM ±3.4%Aug 26 — IV 178% · EM ±35.6%Aug 27 — IV 18% · EM ±3.5%Aug 28 — IV 87% · EM ±16.7%Aug 31 — IV 202% · EM ±35.7%Sep 01 — IV 205% · EM ±35.4%Sep 02 — IV 379% · EM ±63.4%Sep 03 — IV 29% · EM ±4.7%Sep 04 — IV 216% · EM ±33.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in